“We think given the accuracy that this is potentially a game changer,” says Laurence Klotz, MD, FRCSC.
In this video, Laurence Klotz, MD, FRCSC, discusses the miR Sentinel PCC4 Test and how it is advantageous compared to other currently available prostate cancer tests. Klotz is a professor of surgery at the University of Toronto, and the chair of prostate cancer research at the Sunnybrook Health Sciences Centre, Ontario, Canada.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.